These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21712457)

  • 1. Modeling the tumor growth profiles in xenograft experiments--letter.
    Bassukas ID
    Clin Cancer Res; 2011 Jul; 17(13):4612; author reply 4613. PubMed ID: 21712457
    [No Abstract]   [Full Text] [Related]  

  • 2. Biology, models, and the analysis of tumor xenograft experiments.
    Heitjan DF
    Clin Cancer Res; 2011 Mar; 17(5):949-51. PubMed ID: 21224374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
    Zhao L; Morgan MA; Parsels LA; Maybaum J; Lawrence TS; Normolle D
    Clin Cancer Res; 2011 Mar; 17(5):1057-64. PubMed ID: 21131555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling and testing treated tumor growth using cubic smoothing splines.
    Kong M; Yan J
    Biom J; 2011 Jul; 53(4):595-613. PubMed ID: 21604288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model.
    Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM
    Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKPD modeling of acquired resistance to anti-cancer drug treatment.
    Eigenmann MJ; Frances N; Lavé T; Walz AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):617-630. PubMed ID: 29090407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
    Yin X; Luistro L; Zhong H; Smith M; Nevins T; Schostack K; Hilton H; Lin TA; Truitt T; Biondi D; Wang X; Packman K; Rosinski J; Berkofsky-Fessler W; Tang JP; Pant S; Geho D; Vega-Harring S; Demario M; Levitsky H; Simcox M
    Clin Cancer Res; 2013 Oct; 19(20):5686-98. PubMed ID: 23974006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Q&A: John Dick on stem cells and cancer.
    Dick J
    Cancer Discov; 2013 Feb; 3(2):131. PubMed ID: 23400460
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
    Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
    Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stochastic models for tumoral growth.
    Escudero C
    Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Feb; 73(2 Pt 1):020902. PubMed ID: 16605321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of human tumor xenografts and dose rationale in oncology.
    Simeoni M; De Nicolao G; Magni P; Rocchetti M; Poggesi I
    Drug Discov Today Technol; 2013 Sep; 10(3):e365-72. PubMed ID: 24050133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived xenograft (PDX) tumors increase growth rate with time.
    Pearson AT; Finkel KA; Warner KA; Nör F; Tice D; Martins MD; Jackson TL; Nör JE
    Oncotarget; 2016 Feb; 7(7):7993-8005. PubMed ID: 26783960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
    Tan M; Fang HB; Tian GL; Houghton PJ
    Stat Med; 2005 Jan; 24(1):109-19. PubMed ID: 15523707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geometrical approach to tumor growth.
    Escudero C
    Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Aug; 74(2 Pt 1):021901. PubMed ID: 17025466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
    Chen Y; Zhao K; Liu F; Li Y; Zhong Z; Hong S; Liu X; Liu L
    Drug Metab Dispos; 2018 Jun; 46(6):897-907. PubMed ID: 29618575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.